

Live Attenuated Vaccine-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/L36038A5114EN.html

Date: February 2018

Pages: 135

Price: US\$ 2,480.00 (Single User License)

ID: L36038A5114EN

Abstracts

Report Summary

Live Attenuated Vaccine-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Live Attenuated Vaccine industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Live Attenuated Vaccine 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Live Attenuated Vaccine worldwide, with company and product introduction, position in the Live Attenuated Vaccine market Market status and development trend of Live Attenuated Vaccine by types and applications

Cost and profit status of Live Attenuated Vaccine, and marketing status Market growth drivers and challenges

The report segments the global Live Attenuated Vaccine market as:

Global Live Attenuated Vaccine Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America
Europe
China
Japan



Rest APAC

Latin America

Global Live Attenuated Vaccine Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Pediatrics

Adults

Global Live Attenuated Vaccine Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Medical Center Others

Global Live Attenuated Vaccine Market: Manufacturers Segment Analysis (Company and Product introduction, Live Attenuated Vaccine Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma (Japan)

CSL Limited (Australia)

Emergent BioSolutions (U.S.)

GlaxoSmithKline (U.K.)

Johnson & Johnson (U.S.)

MedImmune (U.S.)

Merck & Co (U.S.)

Pfizer (U.S.)

Sanofi Pasteur (France)

Serum Institute of India Pvt (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF LIVE ATTENUATED VACCINE

- 1.1 Definition of Live Attenuated Vaccine in This Report
- 1.2 Commercial Types of Live Attenuated Vaccine
 - 1.2.1 Pediatrics
 - 1.2.2 Adults
- 1.3 Downstream Application of Live Attenuated Vaccine
 - 1.3.1 Hospital
 - 1.3.2 Medical Center
 - 1.3.3 Others
- 1.4 Development History of Live Attenuated Vaccine
- 1.5 Market Status and Trend of Live Attenuated Vaccine 2013-2023
- 1.5.1 Global Live Attenuated Vaccine Market Status and Trend 2013-2023
- 1.5.2 Regional Live Attenuated Vaccine Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Live Attenuated Vaccine 2013-2017
- 2.2 Production Market of Live Attenuated Vaccine by Regions
 - 2.2.1 Production Volume of Live Attenuated Vaccine by Regions
 - 2.2.2 Production Value of Live Attenuated Vaccine by Regions
- 2.3 Demand Market of Live Attenuated Vaccine by Regions
- 2.4 Production and Demand Status of Live Attenuated Vaccine by Regions
- 2.4.1 Production and Demand Status of Live Attenuated Vaccine by Regions 2013-2017
 - 2.4.2 Import and Export Status of Live Attenuated Vaccine by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Production Volume of Live Attenuated Vaccine by Types
- 3.2 Production Value of Live Attenuated Vaccine by Types
- 3.3 Market Forecast of Live Attenuated Vaccine by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Live Attenuated Vaccine by Downstream Industry



4.2 Market Forecast of Live Attenuated Vaccine by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVE ATTENUATED VACCINE

- 5.1 Global Economy Situation and Trend Overview
- 5.2 Live Attenuated Vaccine Downstream Industry Situation and Trend Overview

CHAPTER 6 LIVE ATTENUATED VACCINE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 6.1 Production Volume of Live Attenuated Vaccine by Major Manufacturers
- 6.2 Production Value of Live Attenuated Vaccine by Major Manufacturers
- 6.3 Basic Information of Live Attenuated Vaccine by Major Manufacturers
- 6.3.1 Headquarters Location and Established Time of Live Attenuated Vaccine Major Manufacturer
- 6.3.2 Employees and Revenue Level of Live Attenuated Vaccine Major Manufacturer
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 LIVE ATTENUATED VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Astellas Pharma (Japan)
 - 7.1.1 Company profile
 - 7.1.2 Representative Live Attenuated Vaccine Product
- 7.1.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Astellas Pharma (Japan)
- 7.2 CSL Limited (Australia)
 - 7.2.1 Company profile
 - 7.2.2 Representative Live Attenuated Vaccine Product
- 7.2.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited (Australia)
- 7.3 Emergent BioSolutions (U.S.)
 - 7.3.1 Company profile
 - 7.3.2 Representative Live Attenuated Vaccine Product
- 7.3.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Emergent



BioSolutions (U.S.)

- 7.4 GlaxoSmithKline (U.K.)
 - 7.4.1 Company profile
 - 7.4.2 Representative Live Attenuated Vaccine Product
- 7.4.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (U.K.)
- 7.5 Johnson & Johnson (U.S.)
 - 7.5.1 Company profile
 - 7.5.2 Representative Live Attenuated Vaccine Product
- 7.5.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Johnson & Johnson (U.S.)
- 7.6 MedImmune (U.S.)
 - 7.6.1 Company profile
 - 7.6.2 Representative Live Attenuated Vaccine Product
- 7.6.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of MedImmune (U.S.)
- 7.7 Merck & Co (U.S.)
 - 7.7.1 Company profile
 - 7.7.2 Representative Live Attenuated Vaccine Product
- 7.7.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Merck & Co (U.S.)
- 7.8 Pfizer (U.S.)
 - 7.8.1 Company profile
 - 7.8.2 Representative Live Attenuated Vaccine Product
- 7.8.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)
- 7.9 Sanofi Pasteur (France)
 - 7.9.1 Company profile
 - 7.9.2 Representative Live Attenuated Vaccine Product
- 7.9.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur (France)
- 7.10 Serum Institute of India Pvt (India)
 - 7.10.1 Company profile
 - 7.10.2 Representative Live Attenuated Vaccine Product
- 7.10.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Serum Institute of India Pvt (India)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVE ATTENUATED VACCINE



- 8.1 Industry Chain of Live Attenuated Vaccine
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVE ATTENUATED VACCINE

- 9.1 Cost Structure Analysis of Live Attenuated Vaccine
- 9.2 Raw Materials Cost Analysis of Live Attenuated Vaccine
- 9.3 Labor Cost Analysis of Live Attenuated Vaccine
- 9.4 Manufacturing Expenses Analysis of Live Attenuated Vaccine

CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVE ATTENUATED VACCINE

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Live Attenuated Vaccine-Global Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/L36038A5114EN.html

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/L36038A5114EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970